Finch Therapeutics Group (FNCH) Projected to Announce Earnings on Thursday

Finch Therapeutics Group (NASDAQ:FNCH) is expected to be issuing its resultson Thursday, August 13th. Analysts expect the company to post earnings of ($8.40) per share and revenue of $5.00 million for the quarter.

Finch Therapeutics Group Stock Performance

NASDAQ:FNCH opened at $7.30 on Thursday. The company has a market capitalization of $11.72 million, a price-to-earnings ratio of -0.83 and a beta of 1.18. Finch Therapeutics Group has a one year low of $2.00 and a one year high of $16.10. The stock has a 50-day simple moving average of $7.31 and a 200 day simple moving average of $9.47.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.